SGLT2 Inhibitors

  • The Problem: GTB&S attorneys  are investigating potential claims on behalf of patients who have suffered complications while taking SGLT2 Inhibitors (pills) to treat Type II Diabetes.

  • The Response: The FDA warned the public in 2015 that these Type 2 Diabetic drugs may lead to a life threatening blood condition known as ketoacidosis.

  • What Can We Do to Help:Our experienced attorneys can review your medical records and advise you if filing a case is in your best interest.

The attorneys at Gallon, Takacs, Boissoneault & Schaffer are currently investigating potential claims on behalf of patients who have suffered complications while taking SGLT2 Inhibitors (pills) to treat Type II Diabetes. If you or someone you know has been diagnosed with serious blood condition known as diabetic ketoacidosis, you may be able to file a claim against the manufacturing company for compensation of medical bills, pain and suffering and other damages. Find out if you or someone you know has a claim with a free case evaluation.

Ketoacidosis is a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization for treatment and can result in diabetic coma, brain swelling, or even death.

The FDA WARNED the public on May 15, 2015 that these Type 2 Diabetic drugs may lead to a life threatening blood condition known as ketoacidosis. The FDA FAERS identified 20 cases of acidosis reported as diabetic ketoacidosis (DKA), ketoacidosis, or ketosis in patients treated with SGLT2 Inhibitors from March 2013 through June 6, 2014. Due to the FAERS report, the FDA is currently investigating the safety of SGLT2 Inhibitors to determine if modifications to their drugs prescribing labels are necessary.

The FDA also posted an updated warning on May 16, 2017 about Invokana. Based on new data from two large clinical trials, the FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. FDA is requiring new warnings, including the most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.

SGLT2 Inhibitors the FDA is currently investigating:

  • Invokana (Canagliflozin) tablets
  • Farxiga (Dapagliflozin) tablets
  • Jardiance (Empagliflozin) tablets
  • Invokamet (Canagliflozin and Metformin) tablets
  • Glyxambi (Empagliflozin) tablets

Signs of Ketoacidosis Include:

  • Difficulty Breathing
  • Nausea
  • Vomiting
  • Abdominal Pain
  • Confusion
  • Unusual Fatigue and Sleepiness

Complications arising from Ketoacidosis:

  • Respiratory Distress Syndrome
  • Kidney Failure
  • Swelling of the brain

If you or someone you know taken an SGLT2 Inhibitors to treat Type II Diabetes and have any of the above listed complications, you may be entitled to compensation. The SGLT2 Inhibitors attorneys at Gallon, Takacs, Boissoneault & Schaffer are dedicated to ensuring pharmaceutical companies are held responsible for the dangerous side effects of their products. Call our SGLT2 Inhibitors Attorneys today or fill out the free case evaluation. We want to help you.